Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT) approved for IPF, followed soon after by Boehringer Ingelheim’s nintedanib (Ofev); these therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space, analyzing the clinical and commercial outlook for pirfenidone and nintedanib. We assess emerging therapies, including FibroGen’s IV-administered pamrevlumab and Galapagos’s oral autotoxin inhibitor GLPG-1690. We also examine current medical practice and identify the areas of pressing unmet need in the treatment of the disease.

QUESTIONS ANSWERED

  • How will the size of the IPF population change through 2029? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
  • How do interviewed experts view the clinical profiles of Esbriet and Ofev, and what factors drive or constrain their use? What are the most pressing unmet clinical needs in the management of IPF, according to experts?
  • Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market position of Ofev and Esbriet? What is the commercial potential of pamrevlumab and GLPG-1690?

Table of contents

  • Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Nuno Tiago Giao Antunes, PhD; Devashri Mukherjee, MPH; Natasha Bardhan, M.Pharm

Nuno T. Antunes, Ph.D., is senior business insights analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in antibacterial agents. Previously, he was a Latin America Market Access senior analyst in the Global Market Access Insights Team, where he developed expertise in market access, pricing and reimbursement, health technology assessment, and health policy.

Nuno holds a Ph.D. in animal health from the Universidad de las Palmas de Gran Canaria, Spain, and a D.V.M. degree from the Universidade de Trás-os-Montes e Alto Douro, Portugal. Prior to joining DRG, he conducted research in antimicrobial resistance and antimicrobial development, and worked in the medical devices industry as a scientist.

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.

Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Natasha Bardhan is a Research Associate for the Infectious, Niche, & Rare Diseases (INRD) team at Decision Resources.

Natasha Bardhan holds a bachelor’s degree in Pharmacy from DIPSAR, New Delhi and has completed her master’s in Pharmaceutics from Amity University, Noida. Prior to joining DRG, she worked as a Senior Associate at WNS (Healthcare) for two and a half years. She has worked on multiple client projects involving patents, sales and forecasting, pipeline analysis, keywords research and product/company profiling.


Related Reports

Idiopathic Pulmonary Fibrosis - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary fib...

View Details

Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irr...

View Details

Idiopathic Pulmonary Fibrosis - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological e...

View Details